CLDN18.2
Claudin18.2 is a member of Claudin family proteins, which are mainly
expressed in epithelial cells, and their function is to regulate thepermeability of barrier structures. The structure of Claudin18.2 protein isa four-pass transmembrane protein, as shown in the figure. Claudin18.2
is overexpressed in various malignant tumors, such as breast cancer,

pancreatic cancer (50%), esophageal cancer (30%), etc.

CHcolon cancer, liver cancer, head and neck cancer, lung cancer, andespecially in digestive system tumors, including gastric cancer (70%),

Claudin18.2 is involved in the proliferation, differentiation, and migration of tumor cells. The characteristics of Claudin18.2 (highly overexpressed incancer cells) make it an ideal tumor tumor-associated antigen (TAA) target. Currently, there are different treatment of biological modality targeting on
Claudin18.2 in clinical trials, including monoclonal antibodies, bispecific antibodies, ADC, and CAR-T therapy.

TEDIMA Biotech offers a series of CLDN18.2 products for pre-clinical research needs including bioactive recombinant proteins, biosimilar benchmarkantibody and rabbit monoclonal antibodies to help drug discovery. We also provide pre-validated anti-CLDN18.2 DimAb® B cell libraries, which canenable BioPharma to fish out best candidate lead antibody molecules from pre-immunized B cells in 30-45 days.

O

Monoclonal antibodies against human CLDN18.2

Product Name

BME100075

Anti-CLDN18.2 (zolbetuximab
biosimilar, IMAB-362)

DME100179

Anti-CLDN18.2 antibody (DM179),
Rabbit mAb

BICat. No.

Flow cytometry analysis with Anti-CLDN18.2(DM179) on Expi293 cells transfected with human
CLDN18.2 (Blue) or Expi293 transfected withhuman CLDN18.1 (Green) or Expi293 transfectedwith irrelevant protein (Red).

DIMA

Flow cytometry analysis with Anti-CLDN18.2mAb (zolbetuximab,BME100075 ) on Expi293
cells transfected with human CLDN18.2 (Blue)or Expi293 transfected with CLDN18.1 (Red).

DimAb® Lead mAb molecules and B cell libraries
DIMA provides on-shelf pre-stocked and pre-validated hit-to-lead stage antiCLDN18.2 antibody molecules. Our zero-waiting, zero-risk business model will

not only expediate the pre-clinical development process, but also save the timeand money for pharmaceutical companies.

Through in vitro and in vivo assays, pharmaceutical companies can easily
identify lead drug candidate mAbs for downstream clinical studies from ourDimAb® lead mAb molecules or B cell libraries. Our pre-immunized B cell
libraries can provide a high flexibility for BioPharma during early hit-to-lead

Comparison of DimAb® lead discovery program and traditional leaddiscovery strategies

screening stage. They can directly apply their own assays during earlyscreening. With DIMA’s high throughput single B cloning technology, BioPharma
can obtain lead antibody IgG sequence information within one week time.

400-006-0995

info@dimabio.com

Suzhou / Wuhan

www.dimabio.com

Claudin18.2, A Promising Therapeutic Target
Functional evaluation of different Claudin18.2 CAR constructs
CAR-T Claudin 18.2/K562 – Claudin 18.2GFP-Luc 24 hours of coculture

CAR-T Claudin 18.2/K562 – Claudin 18.1GFP-Luc 24 hours of coculture
Negative control

CAR1
CAR2
CAR3
CAR4
CAR5
BMK CAR control

CAR1
CAR2
CAR3CAR4CAR5BMK CAR control

CH

Negative control

Concentration (pg/mL)

Negative control
CAR1
CAR2
CAR3TE

Concentration (pg/mL)

Concentration (pg/mL)

The target cell killing efficacy of different Claudin18.2 CAR constructs

CAR4
CAR5

BMK CAR control

The measurement of cytokine release

Full-length Bioactive Human CLDN18.2
Recombinant ProteinsO

CLDN18.2 Nanodisc (Cat. No. FLP100014)

ELISA assay to evaluate
CLDN18.2 Nanodisc protein.

ELISA plates were pre-coated with Flag Tag
CLDN18.2-Nanodisc. Serial diluted antiCLDN18.2 monoclonal antibody (Cat. No.
BME100075) solutions were added,washed, and incubated with secondary
antibody before ELISA reading.

Nanodisc

SDS-PAGE

Product Name

FLP100014

Human CLDN18.2 full length proteinsynthetic nanodisc

FLP100006

Human CLDN18.2 full length protein-VLP

FLP100017

Fluorescent Human CLDN18.2 Full Length
Protein-VLP (EGFP)BI

CLDN18.2

Cat. No.

DIMA

CLDN18.2- VLP (Cat. No. FLP100006)

FACS analysis of CLDN18.2 VLP (Cat. No. FLP100006)

A. CLDN18.2 VLP stained with Goat anti-human IgG Fc-PE secondary antibody.
B. Negative VLP control stained with anti-CLDN18.2 antibody (Cat. No. BME100075), followed by Goat anti-human IgG Fc-PE 2nd antibody.
C. CLDN18.2 VLP stained with anti-BCMA antibody, followed by Goat anti-human IgG Fc-PE secondary antibody.
D. CLDN18.2 VLP stained with anti-CLDN18.2 antibody (Cat. No. BME100075), followed by Goat anti-human IgG Fc-PE 2nd antibody.

VLP

ELISA to evaluate CLDN18.2-VLP (Cat. No.
FLP100006) ELISA plates were pre-coated withpurified human CLDN18.2-VLP. Serial diluted AntiCLDN18.2 monoclonal antibody (BME100075) solutions
were added, washed, and incubated with 2nd antibody.

CLDN18.2-EGFP- VLP (Cat. No. FLP100017)

ELISA to evaluate CLDN18.2-EGFPVLP (Cat. No. FLP100017) ELISA plates

were pre-coated with purified human CLDN18.2EGFP-VLP. Serial diluted Anti-CLDN18.2
monoclonal antibody (BME100075) solutions
were added, washed, and incubated with 2ndantibody before ELISA reading.

FACS analysis of CLDN18.2 VLP (Cat. No. FLP100017)

A. Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).
B. Anti-GPRC5D-CAR-Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).
C. Anti-CLDN18.2-CAR-Expi293 cells were stained with biotin labeled Protein L, followed by streptavidin-APC antibody.
D. Anti-CLDN18.2-CAR-Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).

For more products, please visit www.dimabio.com
400-006-0995

info@dimabio.com

Suzhou / Wuhan

www.dimabio.com